Literature DB >> 29153266

Ebola virus disease: an update on post-exposure prophylaxis.

William A Fischer1, Pauline Vetter2, Daniel G Bausch3, Timothy Burgess4, Richard T Davey5, Robert Fowler6, Frederick G Hayden7, Peter B Jahrling8, Andre C Kalil9, Douglas L Mayers10, Aneesh K Mehta11, Timothy M Uyeki12, Michael Jacobs13.   

Abstract

The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resulted in intense efforts to evaluate the efficacy of several specific countermeasures developed through years of preclinical work, including the first clinical trials for therapeutics and vaccines. In this Review, we discuss how the experience and data generated from that outbreak have helped to advance the understanding of the use of these countermeasures for post-exposure prophylaxis against Ebola virus infection. In future outbreaks, post-exposure prophylaxis could play an important part in reducing community transmission of Ebola virus by providing more immediate protection than does immunisation as well as providing additional protection for health-care workers who are inadvertently exposed over the course of their work. We propose provisional guidance for use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for future preparedness and further research.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29153266      PMCID: PMC6636351          DOI: 10.1016/S1473-3099(17)30677-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  100 in total

1.  Clinical care of two patients with Ebola virus disease in the United States.

Authors:  G Marshall Lyon; Aneesh K Mehta; Jay B Varkey; Kent Brantly; Lance Plyler; Anita K McElroy; Colleen S Kraft; Jonathan S Towner; Christina Spiropoulou; Ute Ströher; Timothy M Uyeki; Bruce S Ribner
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

2.  Risk of Misinterpretation of Ebola Virus PCR Results After rVSV ZEBOV-GP Vaccination.

Authors:  Lieselotte Cnops; Michèle Gerard; Olivier Vandenberg; Sigi Van den Wijngaert; Leo Heyndrickx; Elisabeth Willems; Kathy Demeulemeester; Hilde De Clerck; Anne Dediste; Steven Callens; Paul De Munter; Erika Vlieghe; Emmanuel Bottieau; Francoise Wuillaume; Marjan Van Esbroeck; Kevin K Ariën
Journal:  Clin Infect Dis       Date:  2015-02-18       Impact factor: 9.079

3.  Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Authors:  Lilin Lai; Richard Davey; Allison Beck; Yongxian Xu; Anthony F Suffredini; Tara Palmore; Sarah Kabbani; Susan Rogers; Gary Kobinger; Judie Alimonti; Charles J Link; Lewis Rubinson; Ute Ströher; Mark Wolcott; William Dorman; Timothy M Uyeki; Heinz Feldmann; H Clifford Lane; Mark J Mulligan
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

4.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

5.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Authors:  Gary P Kobinger; Heinz Feldmann; Yan Zhi; Gregory Schumer; Guangping Gao; Friederike Feldmann; Steven Jones; James M Wilson
Journal:  Virology       Date:  2005-12-13       Impact factor: 3.616

Review 6.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

7.  Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

Authors:  N M Kudoyarova-Zubavichene; N N Sergeyev; A A Chepurnov; S V Netesov
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

8.  Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.

Authors:  Kentaro Yamada; Kazuko Noguchi; Takashi Komeno; Yousuke Furuta; Akira Nishizono
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

9.  Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Authors:  Thi Huyen Tram Nguyen; Jérémie Guedj; Xavier Anglaret; Cédric Laouénan; Vincent Madelain; Anne-Marie Taburet; Sylvain Baize; Daouda Sissoko; Boris Pastorino; Anne Rodallec; Géraldine Piorkowski; Sara Carazo; Mamoudou N Conde; Jean-Luc Gala; Joseph Akoi Bore; Caroline Carbonnelle; Frédéric Jacquot; Hervé Raoul; Denis Malvy; Xavier de Lamballerie; France Mentré
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

Review 10.  BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease.

Authors:  Raymond Taylor; Pravin Kotian; Travis Warren; Rekha Panchal; Sina Bavari; Justin Julander; Sylvia Dobo; Angela Rose; Yahya El-Kattan; Brian Taubenheim; Yarlagadda Babu; William P Sheridan
Journal:  J Infect Public Health       Date:  2016-04-16       Impact factor: 3.718

View more
  11 in total

Review 1.  Postexposure Effects of Vaccines on Infectious Diseases.

Authors:  Tara Gallagher; Marc Lipsitch
Journal:  Epidemiol Rev       Date:  2019-01-31       Impact factor: 6.222

Review 2.  Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.

Authors:  Yuchen Nan; Yan-Jin Zhang
Journal:  Front Microbiol       Date:  2018-04-20       Impact factor: 5.640

Review 3.  Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof).

Authors:  Prakhar Vijayvargiya; Zerelda Esquer Garrigos; Natalia E Castillo Almeida; Pooja R Gurram; Ryan W Stevens; Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2020-04-30       Impact factor: 7.616

Review 4.  Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.

Authors:  Anahita Fathi; Christine Dahlke; Marylyn M Addo
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

5.  Ebola virus disease nosocomial infections in the Democratic Republic of the Congo: a descriptive study of cases during the 2018-2020 outbreak.

Authors:  April Baller; Maria Clara Padoveze; Patrick Mirindi; Carmen Emily Hazim; Jonathan Lotemo; Jerome Pfaffmann; Aminata Ndiaye; Simone Carter; Marie-Amelie Degail Chabrat; Samuel Mangala; Berthe Banzua; Chantal Umutoni; N'Deye Rosalie Niang; Landry Kabego; Abdoulaye Ouedraogo; Bienvenue Houdjo; Didier Mwesha; Kevin Babila Ousman; Amy Kolwaite; David D Blaney; Mary J Choi; Raymond Pallawo; Anais Legand; Benjamin Park; Pierre Formenty; Joel M Montgomery; Abdou Salam Gueye; Benedetta Allegranzi; N'da Kona Michel Yao; Ibrahima Soce Fall
Journal:  Int J Infect Dis       Date:  2021-12-07       Impact factor: 3.623

Review 6.  CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.

Authors:  Shuliang Chen; Xiao Yu; Deyin Guo
Journal:  Viruses       Date:  2018-01-16       Impact factor: 5.048

7.  Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Authors:  Vincent Madelain; Sylvain Baize; Frédéric Jacquot; Stéphanie Reynard; Alexandra Fizet; Stephane Barron; Caroline Solas; Bruno Lacarelle; Caroline Carbonnelle; France Mentré; Hervé Raoul; Xavier de Lamballerie; Jérémie Guedj
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

Review 8.  Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.

Authors:  Vincent Madelain; France Mentré; Sylvain Baize; Xavier Anglaret; Cédric Laouénan; Lisa Oestereich; Thi Huyen Tram Nguyen; Denis Malvy; Géraldine Piorkowski; Frederik Graw; Stephan Günther; Hervé Raoul; Xavier de Lamballerie; Jérémie Guedj
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-04-28

9.  Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.

Authors:  Chris Davis; Tom Tipton; Suleman Sabir; Celia Aitken; Susan Bennett; Stephan Becker; Tom Evans; Sarah Katharina Fehling; Rory Gunson; Yper Hall; Celia Jackson; Ingolfur Johanssen; Marie Paule Kieny; Jim Mcmenamin; Elizabeth Spence; Thomas Strecker; Catie Sykes; Kate Templeton; Fiona Thorburn; Erica Peters; Ana Maria Henao Restrepo; Beth White; Maria Zambon; Miles W Carroll; Emma C Thomson
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

10.  The Methanolic Extract of Perilla frutescens Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry.

Authors:  Yu-Ting Kuo; Ching-Hsuan Liu; Angela Corona; Elisa Fanunza; Enzo Tramontano; Liang-Tzung Lin
Journal:  Viruses       Date:  2021-09-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.